
-
Your selected country is
Middle East / Africa
- Change country/language
-
Reagents
- Flow Cytometry Reagents
-
Western Blotting and Molecular Reagents
- Immunoassay Reagents
-
Single-Cell Multiomics Reagents
- BD® OMICS-Guard Sample Preservation Buffer
- BD® AbSeq Assay
- BD® Single-Cell Multiplexing Kit
- BD Rhapsody™ ATAC-Seq Assays
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD Rhapsody™ Targeted mRNA Kits
- BD Rhapsody™ Accessory Kits
- BD® OMICS-One Protein Panels
-
Functional Assays
-
Microscopy and Imaging Reagents
-
Cell Preparation and Separation Reagents
-
- BD® OMICS-Guard Sample Preservation Buffer
- BD® AbSeq Assay
- BD® Single-Cell Multiplexing Kit
- BD Rhapsody™ ATAC-Seq Assays
- BD Rhapsody™ Whole Transcriptome Analysis (WTA) Amplification Kit
- BD Rhapsody™ TCR/BCR Next Multiomic Assays
- BD Rhapsody™ Targeted mRNA Kits
- BD Rhapsody™ Accessory Kits
- BD® OMICS-One Protein Panels
- Middle East / Africa (English)
-
Change country/language
Old Browser
This page has been recently translated and is available in French now.
Looks like you're visiting us from {countryName}.
Would you like to stay on the current country site or be switched to your country?
BD Horizon™ PE-CF594 Mouse Anti-Human TIGIT
Clone TgMab-2 (RUO)

Multicolor flow cytometric analysis of TIGIT expression on Human peripheral blood leukocytes. Fresh whole blood was treated with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899) to lyse erythrocytes. After washing, the leukocytes were preincubated with BD Pharmingen™ Human BD Fc Block™ (Cat. No. 564219/564220) and then stained with APC Mouse Anti-Human CD56 (NCAM-1) [Cat. No. 555518; Middle Plots], BD Horizon™ BUV395 Mouse Anti-Human CD4 (Cat. No. 564724), and BD Horizon™ BV421 Mouse Anti-Human CD45RO (Cat. No. 562641/562649; Right Plots) antibodies, and with either BD Horizon™ PE-CF594 Mouse IgG1, κ Isotype Control (Cat. No. 562292; Top Plots) or BD Horizon™ PE-CF594 Mouse Anti-Human TIGIT antibody (Cat. No. 569863/569939; Bottom Plots) as indicated. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software.
Left Plots: The pseudocolor density plot showing the correlated expression of TIGIT (or Ig Isotype control staining) versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of viable leukocyte populations.
Middle Plots: The pseudocolor density plot showing the correlated expression of TIGIT (or Ig Isotype control staining) versus CD56 was derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes.
Right Plots: The pseudocolor density plot showing the correlated expression of TIGIT (or Ig Isotype control staining) versus CD45RO was derived from CD4-positive gated events with the forward and side light-scatter characteristics of viable lymphocytes.


Multicolor flow cytometric analysis of TIGIT expression on Human peripheral blood leukocytes. Fresh whole blood was treated with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899) to lyse erythrocytes. After washing, the leukocytes were preincubated with BD Pharmingen™ Human BD Fc Block™ (Cat. No. 564219/564220) and then stained with APC Mouse Anti-Human CD56 (NCAM-1) [Cat. No. 555518; Middle Plots], BD Horizon™ BUV395 Mouse Anti-Human CD4 (Cat. No. 564724), and BD Horizon™ BV421 Mouse Anti-Human CD45RO (Cat. No. 562641/562649; Right Plots) antibodies, and with either BD Horizon™ PE-CF594 Mouse IgG1, κ Isotype Control (Cat. No. 562292; Top Plots) or BD Horizon™ PE-CF594 Mouse Anti-Human TIGIT antibody (Cat. No. 569863/569939; Bottom Plots) as indicated. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software.
Left Plots: The pseudocolor density plot showing the correlated expression of TIGIT (or Ig Isotype control staining) versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of viable leukocyte populations.
Middle Plots: The pseudocolor density plot showing the correlated expression of TIGIT (or Ig Isotype control staining) versus CD56 was derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes.
Right Plots: The pseudocolor density plot showing the correlated expression of TIGIT (or Ig Isotype control staining) versus CD45RO was derived from CD4-positive gated events with the forward and side light-scatter characteristics of viable lymphocytes.

Multicolor flow cytometric analysis of TIGIT expression on Human peripheral blood leukocytes. Fresh whole blood was treated with BD Pharm Lyse™ Lysing Buffer (Cat. No. 555899) to lyse erythrocytes. After washing, the leukocytes were preincubated with BD Pharmingen™ Human BD Fc Block™ (Cat. No. 564219/564220) and then stained with APC Mouse Anti-Human CD56 (NCAM-1) [Cat. No. 555518; Middle Plots], BD Horizon™ BUV395 Mouse Anti-Human CD4 (Cat. No. 564724), and BD Horizon™ BV421 Mouse Anti-Human CD45RO (Cat. No. 562641/562649; Right Plots) antibodies, and with either BD Horizon™ PE-CF594 Mouse IgG1, κ Isotype Control (Cat. No. 562292; Top Plots) or BD Horizon™ PE-CF594 Mouse Anti-Human TIGIT antibody (Cat. No. 569863/569939; Bottom Plots) as indicated. Flow cytometry and data analysis were performed using a BD LSRFortessa™ X-20 Cell Analyzer System and FlowJo™ software.
Left Plots: The pseudocolor density plot showing the correlated expression of TIGIT (or Ig Isotype control staining) versus side light-scatter (SSC-A) signals was derived from gated events with the forward and side light-scatter characteristics of viable leukocyte populations.
Middle Plots: The pseudocolor density plot showing the correlated expression of TIGIT (or Ig Isotype control staining) versus CD56 was derived from gated events with the forward and side light-scatter characteristics of viable lymphocytes.
Right Plots: The pseudocolor density plot showing the correlated expression of TIGIT (or Ig Isotype control staining) versus CD45RO was derived from CD4-positive gated events with the forward and side light-scatter characteristics of viable lymphocytes.


BD Horizon™ PE-CF594 Mouse Anti-Human TIGIT

Regulatory Status Legend
Any use of products other than the permitted use without the express written authorization of Becton, Dickinson and Company is strictly prohibited.
Preparation And Storage
Recommended Assay Procedures
BD® CompBeads can be used as surrogates to assess fluorescence spillover (compensation). When fluorochrome conjugated antibodies are bound to BD® CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and BD® CompBeads to ensure that BD® CompBeads are appropriate for your specific cellular application.
Product Notices
- Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
- Please observe the following precautions: Absorption of visible light can significantly alter the energy transfer occurring in any tandem fluorochrome conjugate; therefore, we recommend that special precautions be taken (such as wrapping vials, tubes, or racks in aluminum foil) to prevent exposure of conjugated reagents, including cells stained with those reagents, to room illumination.
- Source of all serum proteins is from USDA inspected abattoirs located in the United States.
- Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
- This reagent has been pre-diluted for use at the recommended Volume per Test. We typically use 1 × 10^6 cells in a 100-µl experimental sample (a test).
- For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
- An isotype control should be used at the same concentration as the antibody of interest.
- Texas Red is a registered trademark of Molecular Probes, Inc., Eugene, OR.
- When excited by the yellow-green (561-nm) laser, the fluorescence may be brighter than when excited by the blue (488-nm) laser.
- This product is provided under an Agreement between BIOTIUM and BD Biosciences. The manufacture, use, sale, offer for sale, or import of this product is subject to one or more patents or pending applications owned or licensed by Biotium, Inc. This product, and only in the amount purchased by buyer, may be used solely for buyer’s own internal research, in a manner consistent with the accompanying product literature. No other right to use, sell or otherwise transfer (a) this product, or (b) its components is hereby granted expressly, by implication or by estoppel. This product is for research use only. Diagnostic uses require a separate license from Biotium, Inc. For information on purchasing a license to this product including for purposes other than research, contact Biotium, Inc., 3159 Corporate Place, Hayward, CA 94545, Tel: (510) 265-1027. Fax: (510) 265-1352. Email: btinfo@biotium.com.
- Because of the broad absorption spectrum of the tandem fluorochrome, extra care must be taken when using multi-laser cytometers, which may directly excite both PE and CF™594.
- Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
- CF™ is a trademark of Biotium, Inc.
- For U.S. patents that may apply, see bd.com/patents.
Companion Products






The TgMab-2 monoclonal antibody specifically recognizes TIGIT (T cell Immunoreceptor with Ig and ITIM domains) which is also known as Vstm3 (V-set and transmembrane domain-containing 3), Vsig9 (V-set and Ig domain-containing 9) and WUCAM (Washington University Cell Adhesion Molecule). TIGIT is a 30-34 kDa single pass type I transmembrane glycoprotein that belongs to the CD28 family within the Ig superfamily. TIGIT has an extracellular region with a V-type Ig-like domain, transmembrane sequence, and a cytoplasmic domain with an immunoreceptor tyrosine-based inhibitory motif (ITIM). TIGIT is expressed on NK cells and subsets of activated and memory T cells, regulatory T cells (Treg), and T follicular helper (Tfh) cells. TIGIT binds to CD112 (PVRL2/Nectin-2) and CD155 (PVR/Necl-5) that are expressed on dendritic cells (DC), endothelial cells, fibroblasts, and some tumor cells and can induce IL-10 release and inhibition of IL-12 production. Ligand-bound TIGIT downregulates TCR-mediated T cell activation and proliferation and can block NK cell-mediated cytotoxicity.

Development References (3)
-
Downs-Canner S, Berkey S, Delgoffe GM, et al. Suppressive IL-17A(+)Foxp3(+) and ex-Th17 IL-17A(neg)Foxp3(+) Treg cells are a source of tumour-associated Treg cells.. Nat Commun. 2017; 8:14649. (Biology). View Reference
-
Yasuma K, Yasunaga J, Takemoto K, et al. HTLV-1 bZIP Factor Impairs Anti-viral Immunity by Inducing Co-inhibitory Molecule, T Cell Immunoglobulin and ITIM Domain (TIGIT).. PLoS Pathog. 2016; 12(1):e1005372. (Biology). View Reference
-
Yu X, Harden K, Gonzalez LC, Francesco M, et al. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol. 2009; 10(1):48-57. (Biology). View Reference
Please refer to Support Documents for Quality Certificates
Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described
Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.